The Profile of Patients with Allergic Rhinitis Before and During the Covid-19 Pandemic
DOI:
https://doi.org/10.52783/jns.v14.3998Keywords:
Allergic rhinitis, Total Nasal Symptom Score, COVID-19, pandemicAbstract
Background: Allergic rhinitis is an inflammatory reaction of the nasal mucosa mediated by IgE after exposure to an allergen as an immunological response, with classical symptoms such as a runny nose, sneezing, stuffy nose, nasal itching, red and watery eyes, and discomfort at the hard palate. The number of patients with allergic rhinitis who came to the hospital during the COVID-19 pandemic was affected by the increasing number of cases. The number of patients from March 2018 to February 2020 was 234, while the number of people from March 2020 to February 2022 was 59.
Objective: To identify the profile of patients with allergic rhinitis.
Methods: This research is a retrospective descriptive study using secondary data from medical records. The study population was patients with allergic rhinitis who visited the Allergy-Immunology Division of ORL-HNS outpatient department, Dr. Soetomo General Hospital, Surabaya, from March 2018 to February 2022.
Results: There were a total of 357 people, but only 293 people were included in the research inclusion and exclusion criteria, with the distribution of female patients was 40.96%, the age group of 20-59 years, at 49.49%, and the highest distribution of jobs was entrepreneurs, at 24.23%. The most common symptoms were a runny nose at 24.69%, the most quantitative Total Nasal Symptom Score moderate (5-8) at 47.44%, and the highest moderate-severe persistent classification at 33.79%.
Conclusion: The results showed that there was no significant relationship between age and Total Nasal Symptom Score of the patients, and there is a significant relationship between gender, jobs, clinical symptoms, and classification of allergic rhinitis according to ARIA-WHO of patients who arrived before and during the COVID-19 pandemic.
Downloads
Metrics
References
Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, CanonicaGW, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy ClinImmunol 2010;126(3):466–76.
Mygind N, O’neil JT, Mims JW. Allergic rhinitis. In: Johnson JT, Rosen CA, eds. Bailey’s head and neck surgery otolaryngology. 5th ed. Philadelphia: Lippincot William and Wilkins; 2014.p.460-3.
Cingi C, Gevaert P, Mösges R, Rondon C, Hox V, Rudenko M, et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology task force report. Clin. Transl Allergy 2019; 7:17.
Asmarawati TP, Arfijanto MV, Hadi U, Miftahussurur M. Healthcare associated COVID-19 transmission: strategies to prevent. The New Armenian Medical Journal 2020; 4: 29-36.
Wu Z, McGoogan JM. Characteristics of and important lesson from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Centre for Disease Control and Prevention. JAMA 2020; 323:1239-42.
Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You SG, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol 2020; 146(4): 790-8.
Putranto TA. Keputusan Menteri Kesehatan Republik Indonesia tentang protokol kesehatan bagi masyarakat di tempat dan fasilitas umum dalam rangka pencegahan dan pengendalian COVID-19. Kemenkes RI 2020; 1: 5-9. Availablefrom: http://hukor.kemkes.go.id/uploads/produk_hukum/KMK_No__HK_01_07-MENKES3822020_ttg_Protokol_Kesehatan_Bagi_ Masyarakat_di_Tempat_dan_Fasilitas_Umum_Dalam_Rangka_Pencegahan_COVID-19.pdf Accessed Jun 28, 2022.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.
Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75:1730-41.
Juhn YJ. Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease? J Allergy Clin Immunol 2014;134: 247-57.
Dobashi K, Usami A, Yokozeki H, Tsurikisawa N, Nakamura Y, Sato K, et al. Japanese guidelines for occupational allergic diseases 2020. J Allergology International 2020; 69:387-404.
Kalmarzi RN, Khazaei Z, Shahsavar J, Gharibi F, Tavakol M, Khazaei S, et al. The impact of allergic rhinitis on quality of life: a study in western Iran. Biomed Res Ther 2017; 4(9): 1629-37.
Levin ME, Botha M, Basera W, Facey-Thomas HE, Gaunt B, Gray CL, et al. Environmental factors associated with allergy in urban and rural children from the South African Food Allergy (SAFFA) cohort. J. Allergy Clin. Immunol 2020; 145: 415–26.
Pérez-Herrera LC, Ordoñez-Cerón S, Moreno-López S, Peñaranda D, García E, Peñaranda A, et al. Impact of the COVID-19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia. Laryngoscope Investigate Otolaryngology 2022; 7(2):305-15.
Mahdavinia M, Foster KJ, Jauregui E. Asthma prolongs intubation in COVID-19. The Journal of Allergy and Clinical Immunology In Practice 2020; 8(7):2388–91.
Tham E, Ng PL, Kang A, Shen L, Wong Y. Improved treatment adherence and allergic disease control during a COVID-19 pandemic lockdown. Pediatr Allergy Immunol 2022;33(1): 13688.
Jaruvongvanich V, Mongkolpathumarat P, Chantaphakul H, Klaewsongkram J. Extranasal symptoms of allergic rhinitis are difficult to treat and affect quality of life. Allergology International 2016; 65: 199-203.
Jung S, Lee SY, Yoon JS, Cho HJ, Kim YH, Suh DI, et al. Risk factors and comorbidities associated with the allergic rhinitis phenotype in children according to the ARIA classification. Allergy Asthma Immunol Res 2020; 12(1): 72–85.
Dayal AK, Sinha V. Trend of allergic rhinitis post COVID-19 pandemic: a retrospective observational study. Indian Journal of Otolaryngology and Head & Neck Surgery 2020; 74: 20-2.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
